Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO (Nasdaq: OKYO) announced that an abstract on urcosimod for neuropathic corneal pain (NCP) was accepted for presentation at ARVO 2026 (May 3-7, Denver).
OKYO reported Phase 2a proof-of-concept results showing clinically meaningful pain reduction (VAS), quality-of-life improvement, potential corneal nerve restoration, FDA Fast Track designation, IND clearance, and a planned ~150-patient Phase 2b/3 trial expected to start in the coming months.
OKYO Pharma (Nasdaq: OKYO) priced an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, raising gross proceeds of approximately $20 million. The underwriter has a 30-day option for an additional 1,622,250 shares (proceeds up to ~$23 million).
The offering is expected to close on or about February 17, 2026. Net proceeds will be used primarily for clinical development, general corporate purposes and working capital. Piper Sandler is sole manager; securities offered under an effective Form F-3 (File No. 333-293145).
OKYO Pharma (Nasdaq: OKYO) announced an underwritten public offering of ordinary shares on February 12, 2026. The company will sell all shares offered, with an underwriter option for up to 15% additional shares for 30 days. Piper Sandler is sole book-running manager.
The offering is subject to market conditions and may not be completed. Proceeds are intended primarily for clinical development, general corporate purposes and working capital. The sale is being made from a Form F-3 shelf registration declared effective on February 10, 2026.
OKYO Pharma (Nasdaq: OKYO) transitioned its At-The-Market (ATM) equity offering facility to Leerink Partners as exclusive sales agent, replacing B. Riley Securities. The ATM lets OKYO sell common shares opportunistically at prevailing market prices to support clinical development, including lead candidate urcosimod.
Leerink will receive a 3.0% commission on gross proceeds. Any sales will be made pursuant to a prospectus supplement and base prospectus filed with the SEC. The company emphasized the move enhances financial flexibility without committing to a fixed equity raise.
OKYO Pharma (Nasdaq: OKYO) appointed Flavio Mantelli, MD, PhD as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Mantelli previously led development and approval of Oxervate, which reached $1 billion sales in 2024. OKYO plans a ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026; urcosimod holds FDA Fast Track designation and an authorized compassionate use pathway for NCP.
OKYO Pharma (Nasdaq: OKYO) announced acceptance of a Phase 2 urcosimod abstract for presentation at the 2026 ASCRS Annual Meeting on April 11, 2026 in Washington, DC. The abstract reports efficacy and safety results from a proof-of-concept pilot Phase 2 study, including pain reduction and corneal nerve health trends.
The company notes urcosimod previously received the first IND to treat NCP and FDA fast track designation, and expects to initiate a 150-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma (Nasdaq: OKYO) announced a successful Type C meeting with the FDA on Jan 28, 2026, confirming the proposed Phase 2b/3 design for urcosimod to treat neuropathic corneal pain. The FDA agreed the primary endpoint (VAS pain reduction at Week 12; ≥2-point improvement meaningful), endorsed sample size and powering, supported OPAS as supportive QoL evidence, and aligned on CMC and key clinical elements. OKYO expects to initiate a 120-patient Phase 2b/3 multiple-dose study in the first half of 2026.
OKYO Pharma (Nasdaq: OKYO) announced the FDA authorized a single-patient expanded access Investigational New Drug (IND 176297) application for urcosimod 0.05% to treat a patient with severe neuropathic corneal pain (NCP).
The company said it will provide urcosimod under the physician-sponsored compassionate use IND and noted urcosimod previously received FDA fast track designation. OKYO expects to initiate a 120-patient Phase 2b/3 multiple-dose study of urcosimod for NCP in 2026.
OKYO Pharma (NASDAQ: OKYO) appointed industry veteran Robert J. Dempsey as Chief Executive Officer effective January 5, 2026, with Gary S. Jacob, Ph.D., transitioning to Chief Development Officer and remaining on the Board.
Dempsey brings 20+ years of global ophthalmology experience, led commercialization of Xiidra (sale: $3.4B upfront, up to $1.9B milestones), and oversaw Restasis commercial activities. The Board unanimously approved the leadership change aimed at advancing lead asset urcosimod for neuropathic corneal pain and inflammatory eye disorders.
OKYO Pharma (NASDAQ: OKYO) rang the Opening Bell at Nasdaq MarketSite in Times Square on December 19, 2025 from 9:15 AM to 9:45 AM ET.
The ceremony featured Executive Chairman and Founder Gabriele Cerrone and the management team and celebrated progress on OKYO's clinical pipeline, highlighted by lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting ChemR23 for neuropathic corneal pain (NCP).
The company noted positive Phase 2 results for urcosimod showing favourable corneal nerve outcomes and pain reduction; the bell-ringing was livestreamed on Nasdaq channels.